Sjogren Syndrome

CorneaSicca complexHigh YieldAlso: Sjogren Disease, Sicca Syndrome

Key Points

•Sjogren syndrome is the most common autoimmune cause of dry eye — always consider it in patients with severe aqueous-deficient dry eye, especially women aged 40-60
•Anti-Ro/SSA and anti-La/SSB are the hallmark autoantibodies; a Schirmer test ≤5 mm/5 min indicates severe aqueous tear deficiency
•The 5-10% lifetime risk of non-Hodgkin lymphoma (primarily MALT lymphoma) is the most serious complication — persistent parotid swelling and low C4 are red flags
•Sjogren may be primary (isolated) or secondary to other autoimmune diseases (RA, SLE, systemic sclerosis) — always screen for associated conditions
•Preservative-free artificial tears and topical anti-inflammatory agents (cyclosporine, lifitegrast) are the cornerstones of ocular management

Hallmark Features(Sicca complex)

Keratoconjunctivitis sicca (dry eyes)

Xerostomia (dry mouth)

Lymphocytic infiltration of exocrine glands

Finder Clues

Keratoconjunctivitis siccaXerostomia (dry mouth)Filamentary keratitisRecurrent corneal erosionsBilateral parotid gland enlargementArthralgias / non-erosive arthritisFatiguePeripheral neuropathy

1. Definition

Sjogren syndrome is a chronic autoimmune disorder characterized by lymphocytic infiltration of the lacrimal and salivary glands, resulting in the classic sicca complex of dry eyes (keratoconjunctivitis sicca) and dry mouth (xerostomia). It may be primary (isolated) or secondary (associated with other autoimmune diseases such as rheumatoid arthritis or SLE).

2. Genetics

Genetic associations:

HLA-DR3 and HLA-DQ2 — strongest associations in primary Sjogren syndrome
HLA-B8 — also associated
Familial clustering observed — first-degree relatives have increased risk of autoimmune diseases
Polygenic susceptibility involving genes regulating interferon signaling (STAT4, IRF5) and B-cell activation (BLK, CXCR5)

3. Pathogenesis

Sjogren syndrome is driven by a dysregulated adaptive immune response targeting exocrine glands:

Lymphocytic infiltration (predominantly CD4+ T cells and B cells) of lacrimal and salivary glands
Focal lymphocytic sialadenitis with formation of periductal lymphoid aggregates
Autoantibody production: anti-Ro/SSA and anti-La/SSB target ribonucleoprotein complexes
Type I interferon signature amplifies immune activation
Progressive acinar destruction leads to reduced tear and saliva production
Epithelial cells act as both targets and active participants in immune activation (epithelitis)
Chronic B-cell stimulation creates a risk of lymphoproliferative transformation (MALT lymphoma)

4. Clinical Features

Primary Sjogren syndrome:

Sicca symptoms (dry eyes + dry mouth) — cardinal features
Bilateral parotid enlargement — episodic or chronic
Fatigue — the most debilitating symptom for many patients

Extraglandular manifestations (in 30-40%):

Arthralgias and non-erosive arthritis
Raynaud phenomenon (15-30%)
Interstitial lung disease
Renal tubular acidosis (type 1 distal RTA)
Peripheral neuropathy — sensory > motor
Cutaneous vasculitis — palpable purpura

Secondary Sjogren syndrome:

Occurs with rheumatoid arthritis (most common), SLE, systemic sclerosis, or primary biliary cholangitis

Demographics: Female:male ratio of 9:1; peak onset in 4th-5th decade

5. Ocular Manifestations

Keratoconjunctivitis sicca (KCS) — affects up to 95% of Sjogren patients and is often the earliest manifestation.

Symptoms:

Foreign body sensation, burning, grittiness
Paradoxical reflex tearing (watery eyes) in early disease
Photophobia, blurred vision, mucoid discharge

Signs:

Reduced tear meniscus height (<0.3 mm)
Reduced tear break-up time (<10 seconds)
Punctate epithelial erosions — interpalpebral zone, staining with fluorescein, rose Bengal, and lissamine green
Filamentary keratitis — mucus strands adherent to corneal epithelium
Corneal epithelial defects and recurrent erosions in severe disease
Conjunctival keratinization and loss of goblet cells

Diagnostic tests:

Schirmer I test (without anesthesia): <5 mm wetting in 5 minutes indicates severe aqueous deficiency
Schirmer II test (with anesthesia): measures basal secretion
TBUT <10 seconds — tear film instability
Ocular staining score (Oxford or van Bijsterveld grading)

Complications:

Corneal ulceration and perforation in severe cases
Bacterial keratitis due to compromised ocular surface
Band keratopathy
Scleritis (uncommon but reported)

6. Systemic Manifestations

Glandular:

Xerostomia — difficulty swallowing dry food, rampant dental caries, oral candidiasis
Bilateral parotid enlargement — episodic or persistent
Vaginal dryness, dry skin, dry cough

Extraglandular:

Musculoskeletal — arthralgias, non-erosive arthritis (60%)
Pulmonary — interstitial lung disease, lymphocytic interstitial pneumonia
Renal — type 1 distal renal tubular acidosis, interstitial nephritis
Neurological — peripheral neuropathy (sensory), cranial neuropathies, CNS involvement (rare)
Hematological — cytopenias, hypergammaglobulinemia, cryoglobulinemia
Cutaneous — palpable purpura, annular erythema

Lymphoma risk:

5-10% lifetime risk of developing non-Hodgkin lymphoma (NHL)
Most commonly MALT lymphoma (mucosa-associated lymphoid tissue) of the parotid gland
Risk is 6-9 times higher than the general population
Risk factors: persistent parotid enlargement, palpable purpura, low C4, cryoglobulinemia

7. Diagnosis

ACR/EULAR 2016 Classification Criteria (score ≥4):

Focal lymphocytic sialadenitis (focus score ≥1 on labial salivary gland biopsy) — 3 points
Anti-Ro/SSA antibody positive — 3 points
Ocular staining score ≥5 (or van Bijsterveld ≥4) — 1 point
Schirmer test ≤5 mm/5 min — 1 point
Unstimulated salivary flow ≤0.1 mL/min — 1 point

Autoantibody profile:

Anti-Ro/SSA — positive in 60-70% (most specific for primary SS)
Anti-La/SSB — positive in 30-50% (more specific but less sensitive)
ANA — positive in 80%
Rheumatoid factor — positive in 60-70%
Hypergammaglobulinemia — polyclonal

Imaging:

Sialography — punctate/cavitary pattern (sialectasis)
Parotid ultrasound — inhomogeneous echostructure, hypoechoic foci
MRI — glandular heterogeneity

8. Differential Diagnosis

Causes of keratoconjunctivitis sicca:

Age-related dry eye — most common cause overall; no autoantibodies
Meibomian gland dysfunction — evaporative dry eye; lipid-deficient tears
Medications — antihistamines, anticholinergics, diuretics
Sarcoidosis — granulomatous infiltration of lacrimal gland
IgG4-related disease — lacrimal/salivary gland enlargement, elevated IgG4
Graft-versus-host disease — post-allogeneic transplant
Lymphoma — can directly infiltrate lacrimal glands

Causes of bilateral parotid enlargement:

Sarcoidosis (Heerfordt syndrome)
IgG4-related disease
Viral parotitis (mumps)
Lymphoma
Bulimia (sialadenosis)
HIV-associated diffuse infiltrative lymphocytosis syndrome (DILS)

9. Management

Ocular management (mainstay is tear supplementation and surface protection):

Preservative-free artificial tears — frequent use (q1-2h in severe cases)
Punctal plugs — silicone or collagen plugs to retain tears
Topical cyclosporine 0.05% (Restasis) or lifitegrast 5% (Xiidra) — anti-inflammatory agents for moderate-severe dry eye
Autologous serum tears — for refractory cases
Moisture chamber spectacles
Bandage contact lenses or scleral lenses for severe keratopathy
Topical corticosteroids — short courses for acute flares (avoid chronic use)

Systemic management:

Pilocarpine (5 mg TID) or cevimeline — muscarinic agonists to stimulate residual gland secretion
Hydroxychloroquine — for arthralgias, fatigue, and mild systemic manifestations
Methotrexate or azathioprine — for significant extraglandular disease
Rituximab — for severe systemic manifestations (vasculitis, cytopenias, parotid swelling)

Monitoring:

Regular lymphoma surveillance — especially if parotid enlargement, purpura, or low C4
Dental care — fluoride rinses, frequent dental visits

10. Prognosis

Ocular prognosis:

Chronic, progressive condition requiring lifelong management
Most patients maintain functional vision with appropriate therapy
Severe corneal complications (ulceration, perforation) are uncommon with modern management

Systemic prognosis:

Primary Sjogren syndrome generally has a favorable overall prognosis
Quality of life significantly impacted by fatigue and sicca symptoms
5-10% lifetime risk of lymphoma — the major concern affecting mortality
Mortality is slightly increased compared to the general population, primarily due to lymphoma and infections

Poor prognostic indicators for lymphoma:

Persistent parotid gland enlargement
Palpable purpura
Low C4 complement
Cryoglobulinemia
Lymphopenia

Clinical Pearls

A patient with severe dry eye who also reports difficulty swallowing crackers or dry food should raise immediate suspicion for Sjogren syndrome — always ask about oral dryness

Rose Bengal staining is more sensitive than fluorescein for detecting early conjunctival epithelial damage in Sjogren — but lissamine green is better tolerated and equally effective

Paradoxical watery eyes (reflex tearing) in a patient with dry eye does not rule out Sjogren — the reflex tears are produced in response to ocular surface irritation but lack the mucin and lipid components needed for stability

New-onset or progressively enlarging parotid gland swelling in a known Sjogren patient warrants urgent evaluation for lymphomatous transformation

Mnemonics

DRY EYES Sjogren Workup

D—Dry mouth (xerostomia) and Dry eyes

R—Ro/SSA and La/SSB antibodies

Y—Y chromosome rare (9:1 female predominance)

E—Exocrine gland lymphocytic infiltration

Y—Yield of Schirmer ≤5 mm

E—Evaluate for lymphoma

S—Secondary causes (RA, SLE) to exclude

Diagnostic workup and key features of Sjogren syndrome

Lymphoma Red Flags: PPCC

P—Parotid enlargement (persistent)

P—Purpura (palpable)

C—C4 low

C—Cryoglobulinemia

Risk factors for lymphomatous transformation in Sjogren syndrome